Splicing Factor Mutations in Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Aberrant RNA splicing is a hallmark of many cancers.
• Recurrent somatic mutations in spliceosome genes are increasingly identified in various malignancies.
• Mutations in SF3B1, U2AF1, SRSF2, and ZRSR2 are frequent and largely mutually exclusive.

Purpose of the Study:

• To review the role of spliceosome gene mutations in cancer development.
• To explore the diagnostic and prognostic implications of these mutations.
• To discuss potential therapeutic strategies targeting the spliceosome in cancer.

Main Methods:

• Review of recent literature on spliceosome mutations in cancer.
• Analysis of mutation patterns and their association with clinical phenotypes.
• Discussion of oncogenic mechanisms and therapeutic vulnerabilities.

Main Results:

• SF3B1, U2AF1, SRSF2 mutations are often missense (oncogene-like), while ZRSR2 mutations can be loss-of-function (tumor suppressor-like).
• These mutations are prevalent in hematologic malignancies (e.g., MDS) and occur in solid tumors.
• Mutations are associated with distinct clinical features and have diagnostic/prognostic relevance.
• Mutated splicing factors affect a minority of transcripts, with limited overlap between mutation types.

Conclusions:

• Spliceosome mutations represent key drivers in certain cancers.
• Understanding these mutations provides diagnostic and prognostic insights.
• Targeting the mutated spliceosome machinery offers a promising therapeutic avenue for cancer treatment.